{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:49:27Z","timestamp":1779310167139,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Minimally Invasive Diagnosis and Treatment of Abnormal Uterine of Hebei Province Medical Science Research Key Project","award":["No. 20180143"],"award-info":[{"award-number":["No. 20180143"]}]},{"name":"the Minimally Invasive Diagnosis and Treatment of Abnormal Uterine of Hebei Province Medical Science Research Key Project","award":["No. 20180143"],"award-info":[{"award-number":["No. 20180143"]}]},{"name":"the Minimally Invasive Diagnosis and Treatment of Abnormal Uterine of Hebei Province Medical Science Research Key Project","award":["No. 20180143"],"award-info":[{"award-number":["No. 20180143"]}]},{"name":"the Minimally Invasive Diagnosis and Treatment of Abnormal Uterine of Hebei Province Medical Science Research Key Project","award":["No. 20180143"],"award-info":[{"award-number":["No. 20180143"]}]},{"name":"the Minimally Invasive Diagnosis and Treatment of Abnormal Uterine of Hebei Province Medical Science Research Key Project","award":["No. 20180143"],"award-info":[{"award-number":["No. 20180143"]}]},{"name":"the Minimally Invasive Diagnosis and Treatment of Abnormal Uterine of Hebei Province Medical Science Research Key Project","award":["No. 20180143"],"award-info":[{"award-number":["No. 20180143"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>This trial was to investigate the effect of different treatment methods on the clinical efficacy and fertility outcome of patients with adenomyosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In total, 140 patients with adenomyosis were evenly and randomly allocated into group A (laparoscopic surgery), group B (laparoscopic surgery combined with gonadotropin-releasing hormone analogs [GnRH-a]), group C (ultrasound-guided percutaneous radiofrequency ablation), and group D (ultrasound-guided percutaneous radiofrequency ablation combined with GnRH-a). On the 3rd day after surgery, patients in group B and group D were subcutaneously injected with GnRH-a (Leuprorelin Acetate SR for Injection) at 3.75\u00a0mg\/time, once every 4 weeks, for a total of 3 months. The therapeutic effects of the 4 groups were compared, including menstrual volume, dysmenorrhea score, uterine volume, clinical efficacy, luteinizing hormone (LH), estradiol (E2), and follicle-stimulating hormone (FSH) levels, CA125 levels, recurrence, pregnancy status, and pregnancy outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After treatment, the menstrual volume of 4 groups was lowered, dysmenorrhea, Visual Analog Scale (VAS) score, LH, FSH, E2, and CA125 levels were reduced, and uterine volume was decreased. The menstrual volume, VAS score, levels of LH, FSH, E2, and CA125, and uterine volume were reduced in groups B, C, and D compared with group A, and the decrease was more significant in group D. The total effective rate of group D was 100.00%, which was higher than that of group A (71.43%), group B (80.00%), and group C (82.86%). After one year of drug withdrawal, the recurrence of hypermenorrhea, dysmenorrhea, uterine enlargement, and excessive CA125 in group D was significantly lower than that in groups A, B and C, and the recurrence in groups B and C was significantly lower than that in group A (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Compared with groups A, B, and C, group D had a higher pregnancy rate, natural pregnancy rate, and lower in vitro fertilization-embryo transfer rate (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), but showed no significant difference in pregnancy outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Ultrasound-guided percutaneous radiofrequency ablation combined with Leuprorelin Acetate is effective in the treatment of adenomyosis, which can effectively relieve clinical symptoms, protect postoperative ovarian function, reduce recurrence rate, alleviate pain, and improve quality of life.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-023-01320-0","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T12:02:54Z","timestamp":1705060974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effects of different treatment methods on clinical efficacy and fertility outcomes of patients with adenomyosis"],"prefix":"10.1186","volume":"17","author":[{"given":"Zhaoping","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ligang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suning","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"issue":"10","key":"1320_CR1","doi-asserted-by":"publisher","first-page":"102228","DOI":"10.1016\/j.jogoh.2021.102228","volume":"50","author":"M Bourdon","year":"2021","unstructured":"Bourdon M, et al. Adenomyosis: an update regarding its diagnosis and clinical features. J Gynecol Obstet Hum Reprod. 2021;50(10):102228.","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"2\u201303","key":"1320_CR2","first-page":"129","volume":"38","author":"J Zhai","year":"2020","unstructured":"Zhai J, et al. Adenomyosis: mechanisms and Pathogenesis. Semin Reprod Med. 2020;38(2\u201303):129\u201343.","journal-title":"Semin Reprod Med"},{"key":"1320_CR3","doi-asserted-by":"crossref","unstructured":"Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis F1000Res, 2019. 8.","DOI":"10.12688\/f1000research.17242.1"},{"issue":"5","key":"1320_CR4","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s10815-022-02476-2","volume":"39","author":"G Moawad","year":"2022","unstructured":"Moawad G, et al. Adenomyosis and infertility. J Assist Reprod Genet. 2022;39(5):1027\u201331.","journal-title":"J Assist Reprod Genet"},{"issue":"1","key":"1320_CR5","first-page":"33","volume":"105","author":"S Schrager","year":"2022","unstructured":"Schrager S, et al. Adenomyosis: diagnosis and management. Am Fam Physician. 2022;105(1):33\u20138.","journal-title":"Am Fam Physician"},{"issue":"1","key":"1320_CR6","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1080\/02656736.2021.1939443","volume":"38","author":"L Liu","year":"2021","unstructured":"Liu L, Wang T, Lei B. Image-guided thermal ablation in the management of symptomatic adenomyosis: a systematic review and meta-analysis. Int J Hyperthermia. 2021;38(1):948\u201362.","journal-title":"Int J Hyperthermia"},{"issue":"2","key":"1320_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.4103\/jcrt.JCRT_769_18","volume":"16","author":"C Xu","year":"2020","unstructured":"Xu C, et al. Use of contrast-enhanced ultrasound in evaluating the efficacy and application value of microwave ablation for adenomyosis. J Cancer Res Ther. 2020;16(2):365\u201371.","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"1320_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jmig.2017.07.014","volume":"25","author":"G Younes","year":"2018","unstructured":"Younes G, Tulandi T. Conservative Surgery for adenomyosis and results: a systematic review. J Minim Invasive Gynecol. 2018;25(2):265\u201376.","journal-title":"J Minim Invasive Gynecol"},{"issue":"1","key":"1320_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/02656736.2019.1708481","volume":"37","author":"XL Lin","year":"2020","unstructured":"Lin XL, et al. Comparison between microwave ablation and radiofrequency ablation for treating symptomatic uterine adenomyosis. Int J Hyperthermia. 2020;37(1):151\u20136.","journal-title":"Int J Hyperthermia"},{"key":"1320_CR10","doi-asserted-by":"crossref","unstructured":"Donnez J, Stratopoulou CA, Dolmans MM. Uterine adenomyosis: from Disease Pathogenesis to a New Medical Approach using GnRH antagonists. Int J Environ Res Public Health, 2021. 18(19).","DOI":"10.3390\/ijerph18199941"},{"issue":"4","key":"1320_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00228-021-03256-0","volume":"78","author":"KK Rathinam","year":"2022","unstructured":"Rathinam KK, et al. Evaluation of pharmacological interventions in the management of adenomyosis: a systematic review. Eur J Clin Pharmacol. 2022;78(4):531\u201345.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1320_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1080\/09513590.2021.2000961","volume":"38","author":"M Ji","year":"2022","unstructured":"Ji M, et al. A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea. Gynecol Endocrinol. 2022;38(2):164\u20139.","journal-title":"Gynecol Endocrinol"},{"issue":"5","key":"1320_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.23736\/S0026-4784.18.04316-2","volume":"70","author":"CL Newton","year":"2018","unstructured":"Newton CL, Riekert C, Millar RP. Gonadotropin-releasing hormone analog therapeutics. Minerva Ginecol. 2018;70(5):497\u2013515.","journal-title":"Minerva Ginecol"},{"issue":"9","key":"1320_CR14","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1080\/09513590.2016.1197200","volume":"32","author":"A Pontis","year":"2016","unstructured":"Pontis A, et al. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol. 2016;32(9):696\u2013700.","journal-title":"Gynecol Endocrinol"},{"key":"1320_CR15","doi-asserted-by":"publisher","first-page":"609771","DOI":"10.3389\/fendo.2021.609771","volume":"12","author":"J Lan","year":"2021","unstructured":"Lan J, et al. Ultra-long GnRH Agonist Protocol during IVF\/ICSI improves pregnancy outcomes in women with adenomyosis: a retrospective cohort study. Front Endocrinol (Lausanne). 2021;12:609771.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1320_CR16","doi-asserted-by":"publisher","first-page":"688264","DOI":"10.3389\/fpubh.2021.688264","volume":"9","author":"LL Pang","year":"2021","unstructured":"Pang LL, et al. Efficacy of high-intensity focused Ultrasound Combined with GnRH-a for adenomyosis: a systematic review and Meta-analysis. Front Public Health. 2021;9:688264.","journal-title":"Front Public Health"},{"key":"1320_CR17","doi-asserted-by":"publisher","first-page":"914725","DOI":"10.3389\/fsurg.2022.914725","volume":"9","author":"Z Qin","year":"2022","unstructured":"Qin Z, et al. Application of modified subtotal resection of adenomyosis combined with LNG-IUS and GnRH-a sequential therapy in severe adenomyosis: a case series. Front Surg. 2022;9:914725.","journal-title":"Front Surg"},{"issue":"3","key":"1320_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.fertnstert.2018.01.032","volume":"109","author":"H Osada","year":"2018","unstructured":"Osada H. Uterine adenomyosis and adenomyoma: the surgical approach. Fertil Steril. 2018;109(3):406\u201317.","journal-title":"Fertil Steril"},{"issue":"6","key":"1320_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/09513590.2019.1683818","volume":"36","author":"T Matsushima","year":"2020","unstructured":"Matsushima T, et al. Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest. Gynecol Endocrinol. 2020;36(6):521\u20134.","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"1320_CR20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1080\/02656736.2019.1595179","volume":"36","author":"X Yang","year":"2019","unstructured":"Yang X, et al. Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis. Int J Hyperthermia. 2019;36(1):486\u201392.","journal-title":"Int J Hyperthermia"},{"issue":"Suppl 3","key":"1320_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/1471-0528.14736","volume":"124","author":"Y Guo","year":"2017","unstructured":"Guo Y, et al. Gonadotrophin-releasing hormone agonist combined with high-intensity focused ultrasound ablation for adenomyosis: a clinical study. BJOG. 2017;124(Suppl 3):7\u201311.","journal-title":"BJOG"},{"key":"1320_CR22","doi-asserted-by":"crossref","unstructured":"Dedes I et al. Radiofrequency ablation for adenomyosis. J Clin Med, 2023. 12(9).","DOI":"10.3390\/jcm12093069"},{"issue":"1069","key":"1320_CR23","doi-asserted-by":"publisher","first-page":"20160119","DOI":"10.1259\/bjr.20160119","volume":"90","author":"N Hai","year":"2017","unstructured":"Hai N, et al. Ultrasound-guided transcervical radiofrequency ablation for symptomatic uterine adenomyosis. Br J Radiol. 2017;90(1069):20160119.","journal-title":"Br J Radiol"},{"issue":"1","key":"1320_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/jog.14145","volume":"46","author":"JH Nam","year":"2020","unstructured":"Nam JH. Pregnancy and symptomatic relief following ultrasound-guided transvaginal radiofrequency ablation in patients with adenomyosis. J Obstet Gynaecol Res. 2020;46(1):124\u201332.","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"1320_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/02656736.2021.1874063","volume":"38","author":"N Hai","year":"2021","unstructured":"Hai N, Hou Q, Guo R. Ultrasound-guided transvaginal radiofrequency ablation combined with levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyosis treatment. Int J Hyperthermia. 2021;38(1):65\u20139.","journal-title":"Int J Hyperthermia"},{"key":"1320_CR26","doi-asserted-by":"crossref","unstructured":"Szubert M et al. Adenomyosis and infertility-review of Medical and Surgical approaches. Int J Environ Res Public Health, 2021. 18(3).","DOI":"10.3390\/ijerph18031235"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-023-01320-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-023-01320-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-023-01320-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T12:11:39Z","timestamp":1705061499000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-023-01320-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1320"],"URL":"https:\/\/doi.org\/10.1186\/s13048-023-01320-0","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]},"assertion":[{"value":"22 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest directly related to the contents of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"16"}}